This schedule indicates the recommended age groups and medical indications for routine administration of currently licensed vaccines for persons 19 years and older.
Individuals in this age group should only receive this vaccine as their booster.
Pfizer-BioNTech and Moderna vaccines effective against COVID-19-associated hospitalizations among adults
The approval is indicated for individuals 16 years of age and older, however the vaccine remains available to those aged 12 years and older under the EUA.
Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.